References
- dos Santos AR, Lopes-Costa PV, de Castro JC, et al. Morphometric analysis of the urethra of castrated female rats treated with tamoxifen. Maturitas 2008;59:275–80
- Levine JP. Treating menopausal symptoms with a tissue-selective estrogen complex. Gend Med 2011;8:57–68
- Ortmann O, Lattrich C. The treatment of climacteric symptoms. Dtsch Arztebl Int 2012;109:316–23
- Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
- Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L. Jr A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update 2000;6:2012–24
- Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005;591:247–63
- Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–41
- Polin SA, Ascher SM. The effect of tamoxifen on the genital tract. Cancer Imaging 2008;8:135–45
- Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125–34
- Delmanto A, Nahas-Neto J, Nahas EA, et al. Effect of raloxifene on the vaginal epithelium of postmenopausal women. Eur J Obstet Gynecol Reprod Biol. 2008;139:187–92
- Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric 2005;8:214–20
- Russo J, Russo IH. Biological and molecular bases of mammary carcinogenesis. Lab Invest 1987;57:112–37
- Masson CLP. Tumeurs humaine: histologie, diagnostics et techniques. Paris: Libraire Maloine; 1956
- Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the vaginal health: insights, views & attitudes survey. Menopause 2013;20:1043–8
- Kutner MH, Nachtshein CJ, Neter J, Li W. Applied linear statistical models. 5th ed. Boston: McGraw-Hill Irwin; 2005
- Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661–6
- Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol 2014;139:225–36
- Stika CS. Atrophic vaginitis. Dermatol Ther 2010;23:514–22
- Hascalik S, Celik O, Tamser M, Mizrak B. Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats. Gynecol Obstet Invest 2005;60:186–91
- de Deus JM, Girão MJ, Sartori MG, et al. Glycosaminoglycan profile in bladder and urethra of castrated rats treated with estrogen, progestogen, and raloxifene. Am J Obstet Gynecol 2003;189:1654–9
- dos Santos AR, Lopes-Costa PV, Borges CS, et al. Effects of raloxifene on the urethra of adult castrated female rats. Climacteric 2008;11:483–8
- Jordan VC. An overview of considerations for the testing of tamoxifen as a preventive for breast cancer. Ann N Y Acad Sci 1995;768:141–7
- da Silva BB, Lopes IM, Gebrim LH. Effects of raloxifene on normal breast tissue from premenopausal women. Breast Cancer Res Treat. 2006;95:99–103
- Wang XN, Simmons HA, Salatto CT, et al. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause 2006;13:609–20